Head and Neck Study Progressing Ahead of Schedule
Filed with ASX · · 5 pages · English
Summary by 6ix AI
This stage will focus on obtaining in vivo images during surgery, utilizing Optiscan's InVue™ and InForm™ platforms, and aims to enhance clinical validation and regulatory evidence generation. The accelerated progression is expected to yield time and cost efficiencies while supporting future US FDA submissions and the development of Optiscan's oral cancer AI imaging algorithm. CEO Dr. Camile Farah expressed excitement about the study's progress and its potential to validate Optiscan's imaging technologies in real-world surgical environments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Story so far
Earlier from Optiscan Imaging
- Optiscan Launches InSpecta Device for Veterinary Medicine
- Halfway Mark Reached in Optiscan Breast Cancer Study
- Second Anniversary of Optiscan and Mayo Clinic Agreement
- Optiscan Receives $1.69m R&D Tax Refund
- Optiscan Submits InSpecta FDA Dossier
Later from Optiscan Imaging
- Optiscan Signs New Research Agreement for Breast Study
- Preliminary Final Report
- Optiscan Initiates Head and Neck Cancer Study in the US
- Significant Milestone Reached in ACL Digital Pathology Study
- Optiscan Lodges U.S. FDA 510(k) Submission for InForm
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging